Your browser doesn't support javascript.
Real-world effectiveness of primary series and booster doses of inactivated COVID-19 vaccine against Omicron BA.2 variant infection in China: a retrospective cohort study.
Tang, Lin; Wang, Fu-Zhen; Rodewald, Lance E; Wang, Xuan-Yi; Liu, Si-Yu; Liu, Qian-Qian; Wang, Xiao-Qi; Wu, Dan; Li, Ming-Shuang; Zhang, Qian; Shao, Yi-Ming; Huang, Li-Fang; Song, Yu-Dan; Huang, Yong; Zeng, Xiang; Liu, Li-Jun; Yang, Hong; Huang, Ao-Di; Bao, Li-Ming; Zheng, Hui; Ma, Chao; Lv, Xiao-Ya; Song, Lei; Ma, Zhao; Wang, Shu-Guang; Ma, Hao; Guan, Wei-Jie; Wu, Zhi-Yin; Zhong, Nan-Shan; Yin, Zun-Dong.
  • Tang L; National Immunization Program, Chinese Center for Disease Control and Prevention; Beijing, China.
  • Wang FZ; National Immunization Program, Chinese Center for Disease Control and Prevention; Beijing, China.
  • Rodewald LE; National Immunization Program, Chinese Center for Disease Control and Prevention; Beijing, China.
  • Wang XY; Shanghai Institute of Infectious Disease and Biosecurity, Key Laboratory of Medical Molecular Virology of Ministry of Education & Ministry of Health, and Institutes of Biomedical Sciences; Medical College; Fudan University; Shanghai; China.
  • Liu SY; National Immunization Program, Chinese Center for Disease Control and Prevention; Beijing, China.
  • Liu QQ; National Immunization Program, Chinese Center for Disease Control and Prevention; Beijing, China.
  • Wang XQ; National Immunization Program, Chinese Center for Disease Control and Prevention; Beijing, China.
  • Wu D; National Immunization Program, Chinese Center for Disease Control and Prevention; Beijing, China.
  • Li MS; National Immunization Program, Chinese Center for Disease Control and Prevention; Beijing, China.
  • Zhang Q; National Immunization Program, Chinese Center for Disease Control and Prevention; Beijing, China.
  • Shao YM; State Key Laboratory of Infectious Disease Prevention and Control, National Center for AIDS/STD Control and Prevention; Chinese Center for Disease Control and Prevention Beijing;  China.
  • Huang LF; National Immunization Program, Chinese Center for Disease Control and Prevention; Beijing, China.
  • Song YD; Department of Immunization Program; Fujian Provincial Center for Disease Control and Prevention; Fuzhou; China.
  • Huang Y; National Immunization Program, Chinese Center for Disease Control and Prevention; Beijing, China.
  • Zeng X; National Immunization Program, Chinese Center for Disease Control and Prevention; Beijing, China.
  • Liu LJ; Department of Immunization Program; Guangzhou Center for Disease Control and Prevention; Guangzhou; China.
  • Yang H; National Immunization Program, Chinese Center for Disease Control and Prevention; Beijing, China.
  • Huang AD; China Field Epidemiology Training Program; Chinese Center for Disease Control and Prevention; Beijing; China.
  • Bao LM; Department of Immunization Program; Zhuhai Center for Disease Control and Prevention; Guangzhou; China.
  • Zheng H; National Immunization Program, Chinese Center for Disease Control and Prevention; Beijing, China.
  • Ma C; Department of Immunization Program; Sichuan Provincial Center for Disease Control and Prevention; Chengdu; China.
  • Lv XY; National Immunization Program, Chinese Center for Disease Control and Prevention; Beijing, China.
  • Song L; National Immunization Program, Chinese Center for Disease Control and Prevention; Beijing, China.
  • Ma Z; National Immunization Program, Chinese Center for Disease Control and Prevention; Beijing, China.
  • Wang SG; National Immunization Program, Chinese Center for Disease Control and Prevention; Beijing, China.
  • Ma H; National Immunization Program, Chinese Center for Disease Control and Prevention; Beijing, China.
  • Guan WJ; Development Center for Medicine and Science &Technology; National Health Commission; Beijing; China.
  • Wu ZY; Development Center for Medicine and Science &Technology; National Health Commission; Beijing; China.
  • Zhong NS; Development Center for Medicine and Science &Technology; National Health Commission; Beijing; China.
  • Yin ZD; Development Center for Medicine and Science &Technology; National Health Commission; Beijing; China.
J Infect Dis ; 2023 Apr 03.
Article in English | MEDLINE | ID: covidwho-2283518
ABSTRACT

BACKGROUND:

China has been using inactivated COVID-19 vaccines as primary series and booster doses to protect the population from severe to fatal COVID-19. We evaluated primary and booster vaccine effectiveness (VE) against Omicron BA.2 infection outcomes.

METHODS:

This was a 13-province retrospective cohort study of quarantined close contacts of BA.2-infected individuals. Outcomes were BA.2 infection, COVID-19 pneumonia or worse, and severe/critical COVID-19. Absolute VE was estimated by comparison with an unvaccinated group.

RESULTS:

There were 289,427 close-contacts ≥3 years old exposed to Omicron BA.2 cases; 31,831 turned nucleic-acid amplification test (NAAT)-positive during quarantine, 97.2% with mild or asymptomatic infection, 2.6% had COVID-19 pneumonia, and 0.15% had severe/critical COVID-19. None died. Adjusted VE against any infection was 17% for primary series and 22% when boosted. Primary series aVE in adults >18 years was 66% against pneumonia or worse infection and 91% against severe/critical COVID-19. Booster dose aVE was 74% against pneumonia or worse, and 93% against severe/critical COVID-19.

CONCLUSIONS:

Inactivated COVID-19 vaccines provided modest protection from infection, very good protection against pneumonia, and excellent protection against severe/critical COVID-19. Booster doses are necessary to provide strongest protection.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Topics: Vaccines / Variants Language: English Year: 2023 Document Type: Article Affiliation country: Infdis

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Topics: Vaccines / Variants Language: English Year: 2023 Document Type: Article Affiliation country: Infdis